Each Fund seeks to meet its investment objective by investing in the assets comprising the relevant Index in accordance with the weightings determined and published by the applicable Index Provider.

The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

Benefits of investing in the Global X S&P Biotech ETF

Why CURE?

Diversified exposure to advances in biotechnology

Biotechnology companies focus on the research and development of innovative drugs and treatments that use complex biological materials in their development. Investment in biotech companies can be highly speculative with many companies producing little or no revenue. Outcomes are determined almost entirely on a 'success' or 'failure' metric with high potential rewards for the winners. Investing across the entire sector removes the need to pick winners and gains exposure to overall advancements in the field.

Biotechnology exposure is very different to health care

Biotechnology is a sub-industry of the health care sector, but has very different characteristics to the better-known pharmaceutical sub-industry. Pharma companies tend to be large, well-diversified conglomerates with expertise in mass-production, sales and marketing. Biotech companies, in contrast, are heavily research focused.

Liquidity

CURE holds only stocks trading on major U.S. exchanges and the Index includes filters on market capitalisation and daily trading volume.

Transparent

Full portfolio holdings for CURE are made publicly available daily via https://www.globalxetfs.com.au/funds/cure/

Fund overview

Global X S&P Biotech ETF (CURE) aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index by holding all of the shares that make up the index closely in proportion to their index weights.

This ETF provides exposure to the US biotechnology sub-industry within the health care sector. The fund adopts an equally weighted strategy which gives higher exposure to small and mid-cap stocks held within the fund compared to market capitalisation weighted approach.

Index Description

The S&P Biotechnology Select Industry Index tracks the performance of U.S. listed companies that are classified as belonging to the GICS biotechnology sub-industry and meet certain market capitalisation and liquidity requirements.

Constituents are equally weighted subject to liquidity and the index rebalances quarterly.

Index Objective

The S&P Biotechnology Select Industry Index measure the performance of stocks comprising specific Global Industry Classification Standard (GICS) Biotechnology sub-industry. Membership is based on a company's GICS classification, as well as liquidity and market cap requirements. The index is a modified equal-weight index.

How to use CURE in a Portfolio?

• Alternatives; exposure to growth in the biotechnology thematic

• Tactical tilt towards emerging technologies in the healthcare sector

How we invest your money

Index methodology

The methodology employed by S&P in calculating the Index can be found at www.spindices.com.

To be eligible for inclusion in the Index, a stock must:

• be a member of the S&P Total Market Index,

• be classified as a member of the Biotechnology sub-industry according to GICS, and

• meet certain liquidity and size constraints.

In the event that there are fewer than 35 eligible constituents, then highest market capitalisation stocks classified as members of the Life Sciences Tools & Services sub-industry are added to the Index until it reaches the minimum 35 constituents.

Constituents are equally weighted subject to:

• individual constituent caps related to liquidity, and

• an overall cap of 4.5% per constituent

Investors should review the Index Methodology on the S&P website prior to making an investment.

Index tracking

Each Fund will attempt to (before fees and expenses) fully replicate the performance of the relevant Index by investing its assets in a portfolio of securities that comprise the Index in proportion to the weight assigned to each security within the Index.

Any changes in the composition of an Index, whether due to scheduled rebalancing or other unscheduled events (e.g. corporate actions), will generally be reflected in the portfolio of securities held by a Fund as soon as practically possible.

In certain circumstances, it may not be possible or practical for the Responsible Entity to exactly replicate the Index. For example, trading in particular securities may be suspended. In other circumstances the exact replication of the Index may be impractical or excessively costly, for example where the Index comprises a large number of securities that are assigned small weights.

To assist investors, each Fund's full portfolio holdings will be published on a daily basis on https://www.globalxetfs.com.au/ at the same that Authorised Participants and market makers are provided with portfolio composition files.

Each Fund may hold derivative contracts from time to time, such as exchange traded options written on the Index or its constituent securities, and other investments that do not comprise the Index, but help to achieve the investment objectives of that Fund. These other investments that do not comprise the index may include for example:

• cash or short term deposits;

• related securities such as tradable rights resulting from corporate actions undertaken by Index constituents;

• depository receipts or other securities that may be substituted for Index constituents that are impractical or costly to trade; and

• futures, options, swaps or other ETFs with similar exposures to the Index that may help minimise deviations from the Index, where appropriate.

These are expected to be used in limited circumstances.

Cash balances may also be held in each Fund from time to time. None of the Funds will engage in securities lending.